Venkatesh Kaushik P, Raza Marium M, Diao James A, Kvedar Joseph C
Harvard Medical School, Boston, MA, USA.
NPJ Digit Med. 2022 Aug 10;5(1):112. doi: 10.1038/s41746-022-00662-1.
With the increasing number of FDA-approved artificial intelligence (AI) systems, the financing of these technologies has become a primary gatekeeper to mass clinical adoption. Reimbursement models adapted for current payment schemes, including per-use rates, are feasible for early AI products. Alternative and complementary models may offer future payment options for value-based AI. A successful reimbursement strategy will align interests across stakeholders to guide value-based and cost-effective improvements to care.
随着美国食品药品监督管理局（FDA）批准的人工智能（AI）系统数量不断增加，这些技术的融资已成为大规模临床应用的主要把关因素。适用于当前支付方案（包括按使用费率）的报销模式对早期AI产品是可行的。替代性和补充性模式可能为基于价值的AI提供未来的支付选择。成功的报销策略将使各利益相关方的利益保持一致，以指导基于价值和具有成本效益的医疗改进。
